orphazyme.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Orphazyme |
| Description | Contact Us About Us | Investors & Media | Contact Us About Us Investors & Media Until recently, we were focused on the research and development of novel t |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 34.239.148.132 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
orphazyme.com Valuation
|
US$22,150,169
Last updated: 2023-05-01 10:57:58
orphazyme.com has Semrush global rank of 477,843. orphazyme.com has an estimated worth of US$ 22,150,169, based on its estimated Ads revenue. orphazyme.com receives approximately 2,555,789 unique visitors each day. Its web server is located in United States, with IP address 34.239.148.132. According to SiteAdvisor, orphazyme.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$22,150,169 |
| Daily Ads Revenue | US$20,447 |
| Monthly Ads Revenue | US$613,390 |
| Yearly Ads Revenue | US$7,360,672 |
| Daily Unique Visitors | 170,386 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| orphazyme.com. | A | 600 | IP: 34.239.148.132 |
| orphazyme.com. | NS | 86400 | NS Record: ns2.eurodns.com. |
| orphazyme.com. | NS | 86400 | NS Record: ns3.eurodns.com. |
| orphazyme.com. | NS | 86400 | NS Record: ns4.eurodns.com. |
| orphazyme.com. | NS | 86400 | NS Record: ns1.eurodns.com. |
| orphazyme.com. | MX | 3600 | MX Record: 10 orphazyme-com.mail.protection.outlook.com. |
| orphazyme.com. | TXT | 3600 | TXT Record: SFMC-GwfpIfZcOrxu11GF3aN5JLgG8bGWc1xJN676NXoo |
| orphazyme.com. | TXT | 3600 | TXT Record: 4031C3F8AFE80C7423C2A7988DF910DE0B892991E27AAC28567FC2638BF21D60 |
| orphazyme.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com include:_spf.salesforce.com ~all |
HtmlToTextCheckTime:2023-05-01 10:57:58
| Contact Us About Us | Investors & Media | Contact Us About Us Investors & Media Until recently, we were focused on the research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC). In May 2022, substantially all our assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. Harley-John, living with Niemann-Pick disease type C* Photo courtesy of the NPUK NEWS HIGHLIGHTS VIEW ALL NEWS Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States Company announcement Orphazyme A/S No. 01/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, April 17, 2023 – Orphazyme A/S (ORPHA.CO) Apr 17, 2023 Orphazyme reports financial results in Interim Report First Half 2022 Company announcement Orphazyme A/S No. 36/2022 |
orphazyme.com Whois Information
Domain Name: ORPHAZYME.COM Registry Domain ID: 1560754277_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.eurodns.com Registrar URL: http://www.EuroDNS.com Updated Date: 2021-09-06T14:16:16Z Creation Date: 2009-06-29T15:15:06Z Registry Expiry Date: 2023-06-29T15:15:06Z Registrar: EuroDNS S.A. Registrar IANA ID: 1052 Registrar Abuse Contact Email: legalservices@eurodns.com Registrar Abuse Contact Phone: +352.27220150 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.EURODNS.COM Name Server: NS2.EURODNS.COM Name Server: NS3.EURODNS.COM Name Server: NS4.EURODNS.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-12T10:52:13Z <<< |